The Vall d´Hebron Institute of Oncology (VHIO) Seeks a Laboratory Technician with expertise in next-generation sequencing assays to join its Prostate Cancer Translational Research Group
Immediate Call for Applications
Number of vacancies: 1
We seek a Laboratory Technician to join us at the Vall d´Hebron Institute of Oncology´s (VHIO) Prostate Cancer Translational Research Group, led by Joaquin Mateo to work on the optimization and implementation of next-generation sequencing (NGS) assays using tumour and plasma samples collected from patients with advanced prostate cancer. Specifically, the candidate will be involved in a project supported by a FIS grant from the Instituto de Salud Carlos III (ISCIII) and the Spanish Ministry of Science.
The successful candidate will form an integral part of the scientific team and support the execution of the group’s translational research program, focused on drug development and the study of correlative biomarkers in advanced prostate cancer.
In collaboration with postdoctoral researchers, the selected individual will also be key in developing standard operation procedures (SOPs) for the laboratory in relation to NGS assays.
We are seeking an organized, motivated and team-oriented individual with previous experience working in a translational research laboratory or in a genomics lab, either in the academic or private sector. The candidate should have previous experience in working with human biopsies, DNA and RNA for NGS assays, ideally with prior experience in the field of cancer.
The following requirements are mandatory:
- At least two years’ academic or industry R&D experience with NGS assays.
- Experience in DNA/RNA extraction from human tumour (frozen and FFPE) and plasma samples.
- Experience in NGS library preparation and library capture.
- Knowledge in digital-droplet PCR, qPCR, rtPCR.
- Exceptional attention to detail, scientific rigor, and strong analytical, problem solving, and troubleshooting skills.
Additionally, the following will also be favourably considered:
- Experience with protein-based assays (Western blot, IF).
- Experience with FISH.
- Capable of using ultracentrifugation equipment.
- Basic knowledge of bioinformatics (the candidate will work closely with the group´s bionformaticians).
- Experience with immunohistochemistry assays in human tumour samples.
The candidate is expected to be able to communicate well in English, even if it is not his/her first language.
- Initial 1 year contract to be renewed upon satisfactory appraisal (the project is for 3 years, with the possibility of extension in the future based on performance).
- Estimated annual gross salary: according to profile and experience.
- Start date: July 2019. This could be negotiated if necessary upon discussion with the selected candidate.
Application: Potential candidates should submit a curriculum vitae, letter of intent, and at least one reference using the form below or via email addressed to Joaquin Mateo at: email@example.com, including the reference “Ref. 16-2019” in the subject line of your email. Review of applications will commence immediately; interviews will be arranged with short-listed candidates.
Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO), has established itself as a comprehensive cancer center of proven excellence internationally. It is also thanks to VHIO’s optimal organizational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease.
Located within the Vall d’Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d’Hebron physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients.
VHIO’s pioneering model and programs, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread, and more effectively treating even the most undruggable tumor types.
VHIO’s translation toward precision oncology: https://www.vhio.net.